Shareholder Vote Sought for Cullgen Merger-Related Preferred Stock Conversion, Enabling Significant Dilution

summarizeSummary

Gyre Therapeutics seeks shareholder approval for the conversion of Series B Preferred Stock, which is part of its $300 million all-stock acquisition of Cullgen Inc. This conversion could lead to approximately 19.06% dilution and will trigger major executive and board changes.

check_boxKey Events

• Shareholder Vote on Preferred Stock Conversion

  The company is seeking shareholder approval for the conversion of 3,697,236 shares of Series B Convertible Preferred Stock into 18,486,180 shares of common stock. This approval is required under Nasdaq Listing Rule 5635(a) due to the potential issuance exceeding 20% of outstanding common stock.

• Cullgen Acquisition Details

  The Series B Preferred Stock is being issued as part of the previously announced all-stock acquisition of Cullgen Inc., valued at approximately $300 million. The merger is expected to close in early Q2 2026.

• Significant Potential Dilution

  The conversion of the Series B Preferred Stock would result in the issuance of 18,486,180 common shares, representing approximately 19.06% of the company's currently outstanding common stock.

• Executive and Board Leadership Transition

  Upon completion of the merger, Cullgen's CEO, Dr. Ying Luo, will be appointed as Gyre's Chief Executive Officer and President and will join the Board. Two current directors, Mr. Eastling and Mr. Ma, will resign.

auto_awesomeAnalysis

This preliminary proxy statement outlines proposals for the upcoming annual meeting, with the most significant being the request for shareholder approval to convert Series B Convertible Preferred Stock into common stock. This conversion is directly tied to the previously announced $300 million all-stock acquisition of Cullgen Inc. While the initial issuance of preferred stock is capped at 19.99% of outstanding common stock, the full conversion of these Series B Preferred Shares would result in the issuance of 18,486,180 common shares, representing approximately 19.06% potential dilution to existing shareholders. This approval is necessary to comply with Nasdaq listing rules for transactions exceeding 20% of common stock. The merger will also lead to significant executive and board changes, including Cullgen's CEO, Dr. Ying Luo, becoming Gyre's new CEO and President, and two current directors resigning. This filing is a critical procedural step for a substantial strategic acquisition that will significantly impact the company's capital structure and leadership.